Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Frankfurt - Delayed Quote EUR

China Medical System Holdings Limited (2M7C.F)

Compare
0.9400
0.0000
(0.00%)
At close: April 4 at 5:15:01 PM GMT+2
Loading Chart for 2M7C.F
  • Previous Close 0.9400
  • Open 0.9400
  • Bid 0.9400 x 200000
  • Ask 0.9750 x 200000
  • Day's Range 0.9400 - 0.9400
  • 52 Week Range 0.7100 - 1.1700
  • Volume 300
  • Avg. Volume 16
  • Market Cap (intraday) 2.38B
  • Beta (5Y Monthly) 0.91
  • PE Ratio (TTM) 11.75
  • EPS (TTM) 0.0800
  • Earnings Date Mar 17, 2025
  • Forward Dividend & Yield 0.03 (3.61%)
  • Ex-Dividend Date Apr 28, 2025
  • 1y Target Est --

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. Its products include VALTOCO, a diazepam nasal spray to treat seizure clusters; Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu to treat acute heart failure; Deanxit for mild-to-moderate depression, anxiety, and psychosomatic affections; METOJECT, a methotrexate injection for recalcitrant disabling psoriasis; and Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis. The company also offers Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; ILUMETRI, a tildrakizumab injection to treat moderate-tosevere plaque psoriasis; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. In addition, it provides Aethoxysklerol for sclerotherapy of different varicose veins; Heling Soothing product for skin soothing; Vmonalisa for mid to deep dermal implantation; Neauvia Hyaluronic Acid series; EyeOP1 to treat glaucoma; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; MOVICOL for treating chronic constipation and faecal impaction; and MeteoSpasmyl to treat gastrointestinal flatulence and pain. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.

web.cms.net.cn/zh/home/

4,700

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 2M7C.F

View More

Performance Overview: 2M7C.F

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

2M7C.F
3.87%
HANG SENG INDEX (^HSI)
13.91%

1-Year Return

2M7C.F
55.82%
HANG SENG INDEX (^HSI)
36.62%

3-Year Return

2M7C.F
174.61%
HANG SENG INDEX (^HSI)
1.54%

5-Year Return

2M7C.F
652.42%
HANG SENG INDEX (^HSI)
1.66%

Compare To: 2M7C.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 2M7C.F

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    2.38B

  • Enterprise Value

    1.75B

  • Trailing P/E

    11.17

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.43

  • Price/Book (mrq)

    1.11

  • Enterprise Value/Revenue

    1.86

  • Enterprise Value/EBITDA

    6.00

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    21.69%

  • Return on Assets (ttm)

    5.77%

  • Return on Equity (ttm)

    10.10%

  • Revenue (ttm)

    7.47B

  • Net Income Avi to Common (ttm)

    1.62B

  • Diluted EPS (ttm)

    0.0800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.87B

  • Total Debt/Equity (mrq)

    5.25%

  • Levered Free Cash Flow (ttm)

    544.94M

Research Analysis: 2M7C.F

View More

Company Insights: 2M7C.F

Research Reports: 2M7C.F

View More

People Also Watch